Vanguard Capital Management
CABA icon

Vanguard Capital Management’s Cabaletta Bio CABA Stock Holding History

Vanguard Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Buy
7,227,018
+3,198,027
+79% +$10.5M ﹤0.01% 2382
2026
Q1 		$10.8M Buy
+4,028,991
New +$11.2M ﹤0.01% 2689

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Vanguard Capital Management's CABA Position: Q2 2026 in Review

Vanguard Capital Management increased its Cabaletta Bio (CABA) stake by 79% in Q2 2026, buying an estimated $10.5M and bringing the position to 7,227,018 shares worth $22.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2382.

Vanguard Capital Management first reported a position in CABA in Q1 2026 and has held it in 2 quarters since. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Vanguard Capital Management held 7,227,018 shares of Cabaletta Bio worth $22.5M as of Q2 2026.
  • Vanguard Capital Management bought 3,198,027 Cabaletta Bio shares in Q2 2026, an estimated $10.5M.
  • Cabaletta Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2382 holding.
  • Vanguard Capital Management first reported a position in Cabaletta Bio in Q1 2026 and has held it in 2 quarters since.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.